Sign in
WithdrawnPhase 1/2

Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

Key facts

Who runs it
Sadat City University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
16 Feb 2021
Ended
31 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cilostazol 50 MG
  • Placebo
Record updated
14 July 2025
Why it stopped
Institutional and funding constrains

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adults between 18 and 60 years of age, both men and women,
  • Clinical diagnosis of NAFLD, confirmed by imaging exams,
  • Patients who present levels above the reference values of ALT, AST and ferritin

Who cannot take part

  • Patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - Child Pugh C classification)
  • Users of illicit drugs
  • Patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months
  • Wilson's disease
  • Viral or autoimmune hepatitis
  • HIV virus carriers
  • Patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days
  • Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or -Alzheimer's disease)
  • Women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation
  • Patients with schistosomiasis
  • Hemochromatosis
  • Woman who is breastfeeding
  • Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months
  • Patients who do not participate in all stages of the research

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD. Cilostazol appeared to exert beneficial effects against NAFLD

The 2 groups in the trial

  • CilostazolTreatment being tested

    Treatment: Cilostazol 50 MG

  • PlaceboPlacebo, for comparison

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease: A Randomized, Controlled Trial.
Record updated
14 July 2025